In this video, we discuss the common concerns and misunderstandings about insurance coverage for gynecomastia surgery. Many patients wish for their insurance to cover this procedure, but it's important to understand that this decision is not influenced by the doctor or hospital but solely depends on your insurance policy.

Most insurance companies in India do not cover gynecomastia surgery as it is considered a cosmetic procedure. However, you can communicate with your insurance provider and what documentation we can provide to assist your claim if your insurance policy covers it.

In the video, we also discuss the ethical considerations and why it's important to be honest in your documentation.

Thank you for watching!

Be a part of our Gynecomastia community.

✅ Get insights from our patient community
✅ Ask our board-certified plastic surgeons anything
✅ View the before-and-after patients' results
✅ Connect with other patients & ask them about their experience
✅ First of its a kind initiative in INDIA for patient education and interaction
Join our community: https://drrajatgupta.com/community/
Gynecomastia Helpline: +91 95689 99333

Related Video:
1. Can Gynecomastia be cured non surgically?: https://www.youtube.com/watch?v=kXy5ZyrU-Sk
2. 8 Gynecomastia Surgery Myths: https://www.youtube.com/watch?v=2vzJUdfphc8&t=5s
3. The Ultimate Guide to Gynecomastia Surgery: https://www.youtube.com/watch?v=zFFHjO_uIDw&t=25s
4. Risk involved in Gynecomastia Surgery: https://www.youtube.com/watch?v=vw2diQ-T8K8

------------------------------------------------------------------------------------------------------------------------

About Dr. Rajat Gupta and RG Aesthetics

At RG Aesthetics, India’s best plastic surgeon, Dr. Rajat Gupta is at your service! With 13 years of experience, brand certification, and international recognition, Dr. Gupta is the solution to all your contouring needs.

His expertise in liposuction techniques combined with the state-of-the-art technology available at RG Aesthetics ensures we continue providing the most reliable services with incredible, instantaneous results!

Our equipment allows for every kind of liposuction there is – especially the minimally invasive kinds. Dr. Gupta reflects RG Aesthetics’ belief of the patient’s comfort always being paramount. Procedures at RG Aesthetics, under Dr. Rajat Gupta, minimize trauma and speed up recovery time for the best results!

Schedule a Consultation:
✅ Call: +91 - 9251-711-711
✅ contact@drrajatgupta.com
✅ Visit: https://www.drrajatgupta.com
✅https://www.instagram.com/rajatguptadr
✅https://www.facebook.com/drrajatgupta/
✅https://www.linkedin.com/in/rajat-gupta-9a6b23119/

#gynecomastia #plasticsurgery #insurancecoverage #cosmeticsurgery #healthinsurance #gynecomastiasurgery #medicaladvice #drrajatgupta #delhisurgeon #ckbirlahospital #patienteducation #medicalethics #healthcareindia #rgaesthetics #boardcertifiedplasticsurgeon

A video showing clinical examination of the thyroid gland

Symptoms of carcinoma of the breast

The ABC's of Adult CPR

Tracheal Deviation Technique

As one of the first pediatric centers in the United States to use a new state-of-the-art MRI machine designed especially for kids, Children's Hospital of Michigan continues to deliver world-class, patient-friendly health care. ~ Detroit Medical Center

Combination of Spinal and Epidural for Obstetric analgesia

A new promising technique in saving the lives of patients with cancer of the esophagus. It is minimally invasive and the recovery time is quicker than ever. H. Lee Moffitt Cancer Center

USMLE Step 2 CS - Numbness Weakness This is just preview video. To get full access please visit our website : www.usmletutoring.com

Anatomy of The Infratemporal Fossa

Histology of Aorta

http://www.turkey-ivf.com http://www.tupbebek-istanbul.com We offer a wide range of Assisted Reproductive Technologies including IVF and ICSI (Intracytoplasmic Sperm Injection), Embryo and Sperm Cryopresevation, Intrauterine inseminations (IUI), ovulation induction, Co-Culture (Artificial Uterus). Also other micromanipulation methods (assisted hatching, defragmentation, blastomer biopsy), epididymal or testicular sperm aspiration/extraction (PESA, TESA, TESE or micro TESE) are carried out in our laboratory.

TV interview with Dr. Mostafa Yakoot, MD discussing latest researches on herbal drugs

http://www.landging.com/skeletal-system-animation-knee-surgery.html
This skeletal system animation demonstrates the new concept of knee surgery procedure.

This video shows the heart transplant surgery

Alimentos Para Controlar La Presion Arterial, Arterial Hypertension, Prevencion De Hipertension

http://bajar-presion-arterial.good-info.co

Para obtener los mismos beneficios que los medicamentos prescritos más comúnmente
sin los efectos secundarios negativos existen alternativas naturales. La dieta es la principal manera de aumentar las reacciones deseables, pero el ejercicio contribuye en gran medida también.

Por ejemplo, la misma reacción causada por los vasodilatadores puede ocurrir cuando usted obtiene suficiente L-Arginina. Este aminoácido permite que las paredes de los vasos sanguíneos se relajen. Usted puede tomar un suplemento o conseguirla a través de proteínas de origen animal, el maní y la soja.

http://bajar-presion-arterial.good-info.co


https://www.youtube.com/watch?v=SFUGz4IqbA0
Alimentos Para Controlar La Presion Arterial, Arterial Hypertension, Prevencion De Hipertension, Arterial Pdf, Hipertension Esencial, Hipertension Pulmonar Tratamiento,Tension Alta Sintomas, Dieta Hipertension, Guia Clinica Hipertension, Sal Marina Hipertension,
Sintomas De Tension Alta, Hipertension Portal Pdf, Hipertension Arterial Clasificacion, Hipertension Intracraneal, Tension Alta En, El Embarazo, Hipertension Primaria

Dr. Arthur Handal discusses how injectable fillers can be used to restore a patient's youth.

Interstitial cystitis is a clinical syndrome characterized by daytime and nighttime urinary frequency, urgency, and pelvic pain of unknown etiology. Interstitial cystitis has no clear etiology or pathophysiology, and diagnostic criteria for the syndrome remain undefined. Despite considerable research, universally effective treatments do not exist; therapy usually consists of various supportive, behavioral, and pharmacologic measures. Surgical intervention is rarely indicated. The International Continence Society has coined the term painful bladder syndrome (suprapubic pain with bladder filling associated with increased daytime and nighttime frequency, in the absence of proven urinary infection or other obvious pathology) and reserves the diagnosis of interstitial cystitis for patients with characteristic cystoscopic and histologic features of the condition.[1] An international consensus panel was able to generally agree on the following definition of interstitial cystitis/bladder pain syndrome (IC/BPS): unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder and associated with lower urinary tract symptoms of more than 6 weeks duration, in the absence of infection or other identifiable causes. American Urological Association (AUA) guidelines published in 2011 and amended in 2014 use an evidence-based approach to provide a clinical framework for the diagnosis and management of this condition.[2, 3, 4] In 1887, Skene initially described a condition characterized by inflammation that destroyed the urinary bladder "mucous membrane partly or wholly and extended to the muscular parietes." Guy Hunner popularized the disease with the description of characteristic bladder wall ulcers in association with a symptom complex of chronic bladder inflammation.[5] The first comprehensive epidemiologic description of interstitial cystitis is credited to Hand, who in 1949 described the widespread, small, submucosal bladder hemorrhages and the significant variation in bladder capacity characteristic of the condition. Despite years of intensive research, there are no specific clinical or urinary markers currently clinically available; no absolutely specific radiographic, laboratory, or serologic findings; and no biopsy patterns that are pathognomonic for interstitial cystitis. Some research suggests that the following may all play a role in the disease pathophysiology: (1) pelvic floor dyfunction, (2) dysregulated immune or inflammatory signals, (3) neural hypersensitivity, and (4) disruption of the proteoglycan/glycosaminoglycan (GAG) layer.[6] Interstitial cystitis, howerver, remains a diagnosis of exclusion (see Presentation, DDx, and Workup.) Intensive study has been done to attempt to identify biomarkers for IC/BPS. Some interesting studies have shown that bladder nitric oxide is an accurate marker for Hunner lesions, but these are not present in all patients, and the test requires specific equipment, which has limited widespread clinical use.[7] Differences in levels of cytokines and chemokines, specifically CXCL-10, have shown some ability to differentiate patients with and without Hunner lesions.[8] Other studies of ulcerative IC/BPS have shown that numerous other cytokines and chemokines are up-regulated as well, heralding a possible urinary test to identify patients.[9] An additional substance shown to be up-regulated in IC/BPS patients is antiproliferative factor (APF). This small 8–amino-acid peptide has been associated with suppression of cell growth, increases in transcellular permeability, and lowering of levels of proteins that form intercellular junctional complexes. It is synthesized and secreted from bladder epithelial cells from patients with IC/BPS and may play a key role in pathophysiology.[10] In vitro studies have shown that removal of APF from cell culture media restored cell proliferation and membrane integrity.[11] Studies have also suggested APF in the therapeutic effect of hydrodistension in patients with IC/BPS, although further confirmatory studies are necessary.[12] The most important element in treating patients with interstitial cystitis is education and emotional support. Periodic exacerbations are managed as they occur because no long-term therapy has been shown to prevent or delay recurrent episodes. Therefore, the purpose of treatment is to palliate and alleviate symptoms. Because no discrete pathognomonic pathologic criteria exist for assessing and monitoring disease severity, indications and goals for treatment are based on the degree of patient symptoms. Assessing patient response to treatment is also complicated because of the subjective nature of symptoms; the waxing and waning nature of symptoms without treatment; and the lack of objective serologic, physical, or histopathologic findings. Conservative measures and oral or intravesical treatments are considered first-line treatment. (See Treatment.)

Most individuals with cleft lip (CL), cleft palate (CP), or cleft lip and palate (CLP), as well as many individuals with other craniofacial anomalies, require the coordinated care of providers in many fields of medicine (including otolaryngology) and dentistry, along with that of providers in speech pathology, audiology, genetics, nursing, mental health, and social medicine. Treatment of orofacial cleft anomalies requires years of specialized care and is costly. The average lifetime medical cost for treatment of one individual affected with CLP is $100,000.[2] Although successful treatment of the cosmetic and functional aspects of orofacial cleft anomalies is now possible, it is still challenging, lengthy, costly, and dependent on the skills and experience of a medical team. This especially applies to surgical, dental, and speech therapies. Because otitis media with effusion is very common among children with CP, involvement of an otolaryngologist in the multidisciplinary treatment plan is very important. The otolaryngologist performs placement of ventilation tubes in conjunction with the CP repair.[43] If a concurrent CL is present, the ventilation tubes are placed during that repair. Many of these children see otolaryngologists well beyond the time they see many of the other specialists because some children continue to have eustachian tube dysfunction after their palates are closed.

Pulmonary surfactant is a mixture of lipids and proteins that is produced by alveolar type II epithelial cells (AEC2) and secreted into the airspaces. Phospholipids are the major component of surfactant by weight, and are essential for lowering surface tension at the air-liquid interface, which prevents alveolar collapse at end-expiration. Four proteins highly expressed in the lung and found in surfactant are designated surfactant proteins (SP) A, B, C, and D. Additional proteins including ABCA3 and NKX2.1 are also important for the production of functional surfactant. The surfactant proteins are developmentally regulated, such that their expression increases in later gestation